Trial of innovative digital infection control solution in Manchester NHS FT ICU

曼彻斯特 NHS FT ICU 试用创新数字感染控制解决方案

• 批准号: 10053956
• 金额: $ 45.47万
• 依托单位: PROXXIMOS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10053956
• 关键词: Trial; innovative; digital; infection; control

Our innovative solution is designed to prevent Healthcare Acquired Infections (HCAIs) from spreading around hospitals. The objective of this project is to investigate the solution in the ICU in the Manchester University NHS Foundation Trust (MFT) -- our collaboration partner. This will enable us to develop the solution, certify it and then market it to healthcare customers in the UK and internationally, and create a world-leading company.The solution is based on the concept of digital contact tracing. The aim is to find people infected with a pathogen before they become infectious and spread it to a new host. Without a new host, a pathogen cannot prosper. Our solution exploits wearable technology and is fast, accurate and capable of tackling any communicable pathogen found in a hospital.The benefits of such a project for the NHS are large. 20% of NHS beds are occupied by patients who are overstaying due to HCAIs, and the annual direct treatment costs for these people is £2.8 billion. HCAIs cause 22,000 patient deaths per year (not including Covid-19). If the project is successful, the resulting product could increase NHS capacity by 5-10% whilst saving £1 billion-plus in direct treatment costs. The potential developed world healthcare market is huge (approx. £3 billion).Proxximos has built a prototype in a factory and has secured investment from a Cambridge life sciences VC, and has secured a place in the Knowledge Quarter Labs Accelerator, run by the Francis Crick Institute. With Innovate UK help, we would like to embark on the journey of developing this medical product and commercialising it for healthcare markets in the UK and internationally.

我们的创新解决方案旨在防止医疗获得性感染（HCAIs）在医院周围传播。该项目的目的是调查曼彻斯特大学NHS基金会信托基金（MFT）-我们的合作伙伴-在ICU的解决方案。这将使我们能够开发解决方案，对其进行认证，然后将其推向英国和国际医疗保健客户，并创建一个世界领先的公司。该解决方案基于数字接触追踪的概念。其目的是在感染病原体并将其传播给新宿主之前找到感染病原体的人。如果没有新的宿主，病原体就无法繁殖。我们的解决方案利用可穿戴技术，快速，准确，能够解决医院中发现的任何传染性病原体。这样的项目对NHS的好处是巨大的。20%的NHS床位被因HCAIs而逾期居留的患者占用，这些人每年的直接治疗费用为28亿英镑。HCAIs每年导致22，000名患者死亡（不包括Covid-19）。如果该项目成功，所产生的产品可以将NHS的能力提高5-10%，同时节省10亿英镑以上的直接治疗成本。潜在的发达国家医疗保健市场是巨大的（约。Proxximos已经在一家工厂建造了一个原型，并获得了剑桥生命科学风险投资公司的投资，并在弗朗西斯克里克研究所运营的知识区实验室加速器中获得了一席之地。在Innovate UK的帮助下，我们希望开始开发这种医疗产品，并将其商业化，用于英国和国际医疗市场。